Price Chart

Executive Summary

Aziz Mottiwala, a former officer of Tarsus Pharmaceuticals, filed a Form 144 notice of intent to sell 53,043 shares of common stock, with an approximate market value of $3.82 million based on the filing date. The shares are being sold through Fidelity Brokerage Services LLC and were acquired via stock option exercise. This is a notable insider sale from a former officer, but as a Form 144 it signals intent to sell, not a completed transaction, and the dollar amount is modest relative to the company's $3.1B market cap (approximately 0.12%). Historical calibration data suggests high-score bullish calls on TARS have underperformed, but this is a neutral-to-slightly-bearish insider signal, not a directional call on fundamentals.

Key Facts

• Former officer Aziz Mottiwala filed a Form 144 to sell 53,043 shares of Tarsus common stock.
• The approximate market value of the proposed sale is $3,819,096 based on the filing date.
• Shares were acquired via stock option exercise on August 19, 2026.
• The sale is to be executed through Fidelity Brokerage Services LLC.
• The filing represents intent to sell, not a completed transaction.

Financial Impact

Proposed sale of 53,043 shares valued at approximately $3.82 million, representing ~0.12% of TARS's $3.1B market cap.

Risk Factors

• Insider sale may signal reduced conviction from a former officer.
• Form 144 is only an intent to sell; the actual sale may not occur.
• Historical TARS reports show poor directional accuracy at T+20, suggesting limited predictive value from this filing alone.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status